EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

CD44 is associated with papillary thyroid carcinoma metastasis via potential modulation of the immunosuppressive tumor microenvironment

Yilinuer Adeerjiang, Meng-Han Huo, Li Ma, Xin-Xi Li, Ye Tian, Chao Bai, Bo-Wei Wang, Xia Qu, Xue-Yan Yao, Li-Li Ma, Xiao-Xue Gan, Jun-Yu Kuang und 6 weitere

Clinical and Experimental Medicine · 2026

DOI: 10.1007/s10238-026-02101-x ↗

Kurz gefasst

Fachartikel in der Zeitschrift Clinical and Experimental Medicine, 2026. Verfasst von Yilinuer Adeerjiang und 17 weiteren Autor:innen. Beteiligte Einrichtung: Department of Endocrinology, First Affiliated Hospital of Xinjiang Medical University, Urumqi, China. Hauptthemen laut MEDLINE: Hyaluronan Receptors, Tumor Microenvironment, Thyroid Cancer, Papillary, Thyroid Neoplasms. Die Arbeit nennt 40 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: State Key Laboratory of Pathogenesis, Prevention and Treatment of High Incidence Diseases in Central Asia, Xinjiang Medical University, Xinjiang Tianshan Talent Medical and Health High-level Talent Project, Xinjiang Science and Technology Innovation Team.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

To investigate the role of CD44 in papillary thyroid carcinoma (PTC) lymph node metastasis and its connotation with Treg-mediated immunosuppression through TGF-β and IL-10 signaling. Eighty-two benign thyroid nodule patients were compared with 122 PTC patients. Differentially expressed proteins (DEPs) were identified in both tissue and serum. CD44 expression was validated by ELISA, IHC and flow cytometry. The proportion of Treg and cytokines were analyzed in parallel. The tumor microenvironment architecture was examined using 3D tissue clearing and whole-mount imaging. The functional role of CD44 was further explored using TPC-1 human PTC cell line through gain-of-function and loss-of-function assays in vitro. Proteomic analysis identified 34 tissue and 17 serum DEPs involved in metastasis. CD44 levels in serum were significantly higher in PTC patients than in controls (345.45 ± 44.88 pg/mL vs. 73.33 ± 25.64 pg/mL, P < 0.001). Furthermore, CD44 expression in the serum of CLNM patients was further elevated (782.01 ± 168.38 pg/mL vs. 248.77 ± 55.33 pg/mL, P < 0.001). Multivariate analysis identified CD44 as an independent risk factor for PTC (OR = 5.271, 95% CI: 1.741 ~ 15.959) and CLNM (OR = 3.995, 95% CI: 1.298 ~ 12.298). CD44 levels showed positive correlations with increased TGF-β, IL-10 levels, and Treg frequency. CD44 levels were connected with amplified TGF-β, IL-10, and Treg frequency. IHC and 3D imaging also demonstrated colocalization of CD44⁺ tumor cells and Tregs in H&E sections and whole-mount. Importantly, CD44 knockdown suppressed, while CD44 overexpression enhanced, TPC-1 cell proliferation in vitro, suggesting a direct role of CD44 in promoting tumor cell growth. Our data suggest that CD44 may contribute to PTC metastasis by modulating the immunosuppressive microenvironment through TGF-β/IL-10 mediated Treg accumulation and by directly driving tumor cell proliferation. These findings highlight a potential pathogenic role of CD44 in PTC progression.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Hyaluronan ReceptorsTumor MicroenvironmentThyroid Cancer, PapillaryThyroid NeoplasmsCarcinoma, PapillaryHumansFemaleMiddle AgedAdultMaleTransforming Growth Factor betaCell Line, TumorT-Lymphocytes, RegulatoryInterleukin-10Lymphatic MetastasisProteomics

Stichwörter der Autor:innen

CD44Cervical lymph node metastasis (CLNM)Papillary thyroid carcinoma (PTC)Proteomics

Substanzen

Hyaluronan ReceptorsCD44 protein, humanTransforming Growth Factor betaInterleukin-10

Autor:innen und Institutionen

  • Department of Endocrinology, First Affiliated Hospital of Xinjiang Medical University, Urumqi, China.
  • State Key Laboratory of Pathogenesis, Prevention and Treatment of High Incidence Diseases in Central Asia, Urumqi, China.
  • Department of Gastroenterology and Endocrinology, Tianjin Haihe Hospital, Tianjin, China.
  • Department of Endocrinology, The Friendship Hospital of ILY Kazak Autonomous Pefecture, Yining, China.
  • Department of Endocrine surgery, First Affiliated Hospital of Xinjiang Medical University, Urumqi, China.
  • Department of Pathology, First Affiliated Hospital of Xinjiang Medical University, Urumqi, China.

Förderung

  • State Key Laboratory of Pathogenesis, Prevention and Treatment of High Incidence Diseases in Central Asia, Xinjiang Medical University
  • Xinjiang Tianshan Talent Medical and Health High-level Talent Project
  • Xinjiang Science and Technology Innovation Team
  • the Xinjiang Youth Science and Technology Top Talents Special Project
  • Youth Science Fund Project
  • National Natural Science Foundation of China
  • Xinjiang Bayingolin Mongolian Autonomous Prefecture "Open bidding for selecting the best candidates" project
  • Science and Technology Research Plan

Zitieren

APA

Adeerjiang, Y., Huo, M. H., Ma, L., Li, X. X., Tian, Y., Bai, C., Wang, B. W., Qu, X., Yao, X. Y., Ma, L. L., Gan, X. X., Kuang, J. Y., Liang, H. Z., Qiang, B. R., Wang, R., Bao, J. L., Jiang, S., & Du, G. L. (2026). CD44 is associated with papillary thyroid carcinoma metastasis via potential modulation of the immunosuppressive tumor microenvironment. Clinical and Experimental Medicine. https://doi.org/10.1007/s10238-026-02101-x

Vancouver

Adeerjiang Y, Huo MH, Ma L, Li XX, Tian Y, Bai C, et al. CD44 is associated with papillary thyroid carcinoma metastasis via potential modulation of the immunosuppressive tumor microenvironment. Clinical and Experimental Medicine. 2026. doi:10.1007/s10238-026-02101-x

BibTeX
@article{Adeerjiang2026,
  author = {Adeerjiang, Yilinuer and Huo, Meng-Han and Ma, Li and Li, Xin-Xi and Tian, Ye and Bai, Chao and Wang, Bo-Wei and Qu, Xia and Yao, Xue-Yan and Ma, Li-Li and Gan, Xiao-Xue and Kuang, Jun-Yu and Liang, Hua-Zheng and Qiang, Bo-Rong and Wang, Rui and Bao, Jian-Ling and Jiang, Sheng and Du, Guo-Li},
  title = {CD44 is associated with papillary thyroid carcinoma metastasis via potential modulation of the immunosuppressive tumor microenvironment},
  journal = {Clinical and Experimental Medicine},
  year = {2026},
  doi = {10.1007/s10238-026-02101-x}
}
Kostenlos starten →